Tivozanib
- Generic Name
- Tivozanib
- Brand Names
- Fotivda
- Drug Type
- Small Molecule
- Chemical Formula
- C22H19ClN4O5
- CAS Number
- 475108-18-0
- Unique Ingredient Identifier
- 172030934T
- Background
Renal cell carcinoma (RCC) is responsible for 3% of cancer cases and is one of the 10 most common cancers in adults. The average age of diagnosis is between age 65 to 74. Tivozanib, also known as FOTIVDA, is a kinase inhibitor developed to treat adult patients with relapsed or refractory advanced renal cell carcinoma (RCC) after prior failed systemic therapi...
- Indication
适用于治疗既往两种或多种全身治疗后复发或难治性晚期肾细胞癌（RCC）的成年患者。
- Associated Conditions
- Advanced Renal Cell Carcinoma, Renal Cell Carcinoma (RCC)
- Associated Therapies
- -
Tivozanib for Recurrent Glioblastoma
- First Posted Date
- 2013-05-03
- Last Posted Date
- 2019-01-08
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 10
- Registration Number
- NCT01846871
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
Tivozanib + Gemcitabine in Metastatic RCC
- First Posted Date
- 2013-04-17
- Last Posted Date
- 2013-06-19
- Lead Sponsor
- Dana-Farber Cancer Institute
- Registration Number
- NCT01834183
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸Brigham and Women's Hospital, Boston, Massachusetts, United States
Phase II Trial of Tivozanib in Advanced Hepatocellular Cancer
- First Posted Date
- 2013-03-08
- Last Posted Date
- 2016-04-22
- Lead Sponsor
- Emory University
- Target Recruit Count
- 7
- Registration Number
- NCT01807156
- Locations
- 🇺🇸
Emory University, Winship Cancer Institute, Atlanta, Georgia, United States
A Phase II Study of Tivozanib in Patients With Metastatic and Non-resectable Soft Tissue Sarcomas
- Conditions
- Interventions
- First Posted Date
- 2013-02-01
- Last Posted Date
- 2019-09-09
- Lead Sponsor
- Northwestern University
- Target Recruit Count
- 58
- Registration Number
- NCT01782313
- Locations
- 🇺🇸
Northwestern University, Chicago, Illinois, United States
🇺🇸University of Wisconsin, Madison, Wisconsin, United States
🇺🇸University of Iowa, Iowa City, Iowa, United States
Tivozanib Before Surgery in Treating Patients With Localized Kidney Cancer
- Conditions
- Interventions
- First Posted Date
- 2013-01-17
- Last Posted Date
- 2022-08-15
- Lead Sponsor
- Roswell Park Cancer Institute
- Registration Number
- NCT01769885
A Phase I/II Study of Tivozanib and Erlotinib as Initial Treatment for Metastatic Non-small Cell Lung Cancer Assigned by VeriStrat® Serum Proteomic Evaluation
- Conditions
- Interventions
- First Posted Date
- 2012-11-16
- Last Posted Date
- 2013-07-25
- Lead Sponsor
- University of Utah
- Registration Number
- NCT01728181
A Subject Treatment Preference Study of Tivozanib Versus Sunitinib in Subjects With Metastatic RCC
- Conditions
- Interventions
- First Posted Date
- 2012-08-28
- Last Posted Date
- 2020-10-27
- Lead Sponsor
- AVEO Pharmaceuticals, Inc.
- Target Recruit Count
- 58
- Registration Number
- NCT01673386
A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy
- Conditions
- Interventions
- First Posted Date
- 2011-11-23
- Last Posted Date
- 2015-07-08
- Lead Sponsor
- AVEO Pharmaceuticals, Inc.
- Target Recruit Count
- 265
- Registration Number
- NCT01478594
- Locations
- 🇺🇸
Kaiser Foundation Hospitals, Honolulu, Hawaii, United States
🇨🇦Hopital Saint-Luc - Pavillon Principal, Montreal, Quebec, Canada
🇺🇸Associates of Oncology Hematology, P.C., Rockville, Maryland, United States
A Rollover Protocol to Allow Continued Access to Tivozanib (AV 951) for Subjects Enrolled in Other Tivozanib Protocols
- Conditions
- Interventions
- First Posted Date
- 2011-06-09
- Last Posted Date
- 2020-09-01
- Lead Sponsor
- AVEO Pharmaceuticals, Inc.
- Target Recruit Count
- 225
- Registration Number
- NCT01369433
- Locations
- 🇺🇸
Florida Cancer Specialists, Fort Myers, Florida, United States
🇺🇦AVEO Investigational Site, Zaporizhya, Ukraine
🇺🇸Jayne Gurtler MD, Laura Brinz MD, Angelo Russo MD and Janet Burroff MD APMC, Metairie, Louisiana, United States
A Phase 1 Study to Evaluate the Effect of Rifampin on the Pharmacokinetics of Tivozanib in Healthy Subjects
- First Posted Date
- 2011-06-02
- Last Posted Date
- 2012-06-05
- Lead Sponsor
- AVEO Pharmaceuticals, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT01363804
- Locations
- 🇺🇸
Covance Clinical Research Unit, Inc., Daytona Beach, Florida, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.